Pioglitazone vs Glipizide for Type 2 Diabetes Management

Introduction to Key Decision Points

The American Heart Association states that thiazolidinediones, such as pioglitazone, are contraindicated in heart failure, as they double the risk of HF hospitalization 7.
Pioglitazone should be chosen over glipizide in patients with type 2 diabetes and non-alcoholic steatohepatitis (NASH) with significant fibrosis (F2 or greater), as it reverses steatohepatitis in 47% of patients and may slow fibrosis progression 1, 2.
Pioglitazone reduces recurrent stroke risk in patients with prior ischemic stroke or transient ischemic attack (TIA) and insulin resistance 3, 4.

Pioglitazone decreases triglycerides by 31.62 mg/dL more than sulfonylureas and increases HDL-cholesterol by 4.27 mg/dL, whereas glipizide does not improve and may worsen lipid profiles 5, 6.
The American College of Cardiology recommends considering pioglitazone for patients with type 2 diabetes and established cardiovascular disease without heart failure, as it offers net cardiovascular benefit despite heart failure risk 7, 3.
Pioglitazone reduces cardiovascular events, including cardiovascular death, myocardial infarction, or stroke, but increases heart failure hospitalizations 7, 3.

Pioglitazone demonstrates superior durability of glycemic control compared to sulfonylureas, with better maintenance of HbA1c levels at 52 weeks 4.
Sulfonylureas, such as glipizide, increase the risk of mild-to-moderate hypoglycemia 4.6-fold compared to other agents, whereas pioglitazone has minimal hypoglycemia risk when used as monotherapy 5.
In elderly patients or those at high risk for falls, pioglitazone is safer regarding hypoglycemia 11.

The European Association for the Study of Diabetes recommends screening for absolute contraindications to pioglitazone, including current heart failure and active liver disease, before initiating treatment 7, 11.
Patients with non-alcoholic steatohepatitis (NASH) with significant fibrosis (F2 or greater) should be treated with pioglitazone, as it reverses steatohepatitis and may slow fibrosis progression 1, 2.
Patients with prior stroke or transient ischemic attack (TIA) and insulin resistance should be treated with pioglitazone, as it reduces recurrent stroke risk 3, 4.

Patients treated with pioglitazone should be monitored for edema and heart failure symptoms at each visit, as well as liver enzymes at baseline and periodically 7, 11.
Patients treated with glipizide should be monitored for hypoglycemia, especially in the elderly, and have their dose adjusted with declining renal function 5, 11.